| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-12-07 | CTL019 (tisagenlecleucel-T) | acute lymphoblastic leukemia (ALL) | Novartis (Switzerland) | Cancer - Oncology | |
| 2013-12-06 | RP6530 | advanced hematological malignancies |
1 | Rhizen Pharmaceuticals (Switzerland) | Cancer - Oncology |
| 2013-12-06 | NBTX-TOPO | Nanobiotix (France) | Cancer - Oncology | ||
| 2013-12-05 | kinase inhibitor program | advanced cancer |
1 | Bayer (Germany) | Cancer - Oncology |
| 2013-12-05 | Carragelose®-based nasal spray | common cold | Marinomed Biotechnologie (Austria) | Infectious diseases | |
| 2013-12-04 | Alprolix® (eftrenonacog alfa - long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) - BIIB 029 | hemophilia B | 3 | BiogenIdec (USA) Swedish Orphan Biovitrum SOBI (Sweden) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2013-12-04 | MEDI9929 (AMG 157) | severe asthma |
2 | AstraZeneca (UK) Amgen (USA - CA) | Allergic diseases – Inflammatory diseases – Respiratory diseases |
| 2013-12-04 | Xtandi® (enzalutamide) | breast cancer | 2 | Medivation (USA - CA) Astellas (Japan) | Cancer - Oncology |
| 2013-12-03 | Xtandi® (enzalutamide) | non metastatic prostate cancer | 3 | Medivation (USA - CA) Astellas (Japan | Cancer - Oncology |
| 2013-12-02 | non-invasive blood tests for early detection and prognosis of colorectal cancer | colorectal cancer | prospective study | VolitionRX (Singapore) Belgian Volition (Belgium) CHU UCL Mont-Godinne Hospital (Belgium) | Cancer - Oncology |
| 2013-12-02 | macitentan | reduction of the number of new digital ulcers in patients with systemic sclerosis |
3 | Actelion (Switzerland) | Autoimmune diseases |
| 2013-12-01 | VAC-3S immunotherapy | HIV/Aids | 2 | Innavirvax (France) | Infectious diseases |
| 2013-12-00 | HuMax®-TF-ADC | solid tumors ( ovarian cancer, cervix cancer endometrium cancer, bladder cancer, prostate cancer, esophagus cancer, lung cancer) |
1 | Genmab (Denmark) | Cancer - Oncology |
| 2013-11-27 | VB-111 (ofranergene obadenovec) | glioblastoma multiforme (GBM) | 2 | VBL Therapeutics (Israel) | Cancer - Oncology |
| 2013-11-21 | AMG 232 | acute myeloid leukemia | 1 | Amgen (USA - CA) | Cancer - Oncology |
| 2013-11-21 | trametinib and palbociclib | melanoma |
1-2 | GSK (UK) Pfizer (USA - NY) | Cancer - Oncology |
| 2013-11-20 | methylated SHOX2 | lung cancer | Epigenomics (Germany - USA) | Cancer - Oncology | |
| 2013-11-19 | OC459 | atopic dermatitis |
2 | Atopix Therapeutics (UK) | Dermatological diseases - Immunological diseases - Inflammatory diseases |
| 2013-11-18 | SAR302503 (fedratinib) | myelofibrosis | 3 | Sanofi (France) | Rare diseases |
| 2013-11-16 | lampalizumab | geographic atrophy (advanced form of dry age-related macular degeneration (AMD) | 2 | Roche (Switzerland) | Ophtalmological diseases |
